Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Maraviroc

FDA-approved product (tablet, oral), marketed as Maraviroc, Selzentry.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Maraviroc
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antivirals
FDA pharmacologic class
CCR5 Co-receptor Antagonist FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Maraviroc in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Maraviroc with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

    NCT01627717 · start 2012-06

    Registered record
    Registry ID
    NCT01627717
    Conditions
    Healthy
    Interventions
    Maraviroc (5 days); Maraviroc and boceprevir (14 days)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2014-02
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc (5 days); Maraviroc and boceprevir (14 days)
    PhasePhase 1
    Registry statusCompleted

  • Effects of Intensive cART During Acute/Early HIV Infection

    NCT01154673 · start 2011-11

    Registered record
    Registry ID
    NCT01154673
    Conditions
    Acute HIV Infection
    Interventions
    raltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute HIV Infection
    Interventionraltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

    NCT01348763 · start 2011-10

    Registered record
    Registry ID
    NCT01348763
    Conditions
    HIV
    Interventions
    Maraviroc; Truvada; Darunavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-10
    Completion
    2012-05
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionMaraviroc; Truvada; Darunavir
    PhasePhase 1
    Registry statusCompleted

  • Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)

    NCT01367210 · start 2011-06

    Registered record
    Registry ID
    NCT01367210
    Conditions
    HIV Infection
    Interventions
    Maraviroc, Darunavir/r; current antiretroviral therapy with 3 drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-06
    Completion
    2015-06
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionMaraviroc, Darunavir/r; current antiretroviral therapy with 3 drugs
    PhasePhase 4
    Registry statusTerminated

  • R5 Integrase Study in HIV-1 Naive Patients

    NCT01204905 · start 2010-09

    Registered record
    Registry ID
    NCT01204905
    Conditions
    HIV Infections
    Interventions
    Raltegravir and Maraviroc in combination
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-09
    Completion
    2014-05-16
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRaltegravir and Maraviroc in combination
    PhaseNot applicable
    Registry statusCompleted

  • Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

    NCT01056874 · start 2010-03

    Registered record
    Registry ID
    NCT01056874
    Conditions
    Healthy; HIV Infections
    Interventions
    Digoxin; Digoxin; Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; HIV Infections
    InterventionDigoxin; Digoxin; Maraviroc
    PhasePhase 1
    Registry statusCompleted

  • Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

    NCT00981318 · start 2009-12

    Registered record
    Registry ID
    NCT00981318
    Conditions
    HIV Infections; Acquired Immunodeficiency Syndrome
    Interventions
    lopinavir/ritonavir plus maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2009-12
    Completion
    2015-05
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Acquired Immunodeficiency Syndrome
    Interventionlopinavir/ritonavir plus maraviroc
    PhasePhase 4
    Registry statusTerminated

  • Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

    NCT00988780 · start 2009-12

    Registered record
    Registry ID
    NCT00988780
    Conditions
    Immune Reconstitution Inflammatory Syndrome; HIV; HIV Infections
    Interventions
    maraviroc; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2009-12
    Completion
    2013-04
    Enrolment
    276

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Reconstitution Inflammatory Syndrome; HIV; HIV Infections
    Interventionmaraviroc; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

    NCT00944541 · start 2009-09

    Registered record
    Registry ID
    NCT00944541
    Conditions
    HIV Infection; HIV Infections
    Interventions
    maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09
    Completion
    2011-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; HIV Infections
    Interventionmaraviroc
    PhasePhase 2
    Registry statusCompleted

  • Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

    NCT00850395 · start 2009-07

    Registered record
    Registry ID
    NCT00850395
    Conditions
    HIV-1
    Interventions
    maraviroc
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-07
    Completion
    2011-10
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    Interventionmaraviroc
    PhaseNot recorded
    Registry statusCompleted

  • Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term

    NCT01060618 · start 2009-05

    Registered record
    Registry ID
    NCT01060618
    Conditions
    HIV Infections
    Interventions
    Maraviroc + Trofile ESTA® (diagnose test)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2011-12
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionMaraviroc + Trofile ESTA® (diagnose test)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

    NCT00870363 · start 2009-04

    Registered record
    Registry ID
    NCT00870363
    Conditions
    HIV Infections
    Interventions
    maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2013-04
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionmaraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
    PhasePhase 4
    Registry statusCompleted

  • Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection

    NCT00879047 · start 2009-04

    Registered record
    Registry ID
    NCT00879047
    Conditions
    HIV Infections; Hepatitis C
    Interventions
    Alcohol; Alcohol placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2013-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Hepatitis C
    InterventionAlcohol; Alcohol placebo
    PhasePhase 1
    Registry statusCompleted

  • Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects

    NCT00884858 · start 2009-04

    Registered record
    Registry ID
    NCT00884858
    Conditions
    HIV Infections
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2011-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionMaraviroc
    PhasePhase 4
    Registry statusCompleted

  • Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

    NCT00782301 · start 2009-03

    Registered record
    Registry ID
    NCT00782301
    Conditions
    Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
    Interventions
    maraviroc; etravirine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-03
    Completion
    2010-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
    Interventionmaraviroc; etravirine
    PhasePhase 4
    Registry statusWithdrawn